Meeting Banner
Abstract #0552

Prostate Cancer Detection Rate: MRSI Directed TRUS Biopsy Versus Increasing Number of Cores in Clinically Challenging Group of Men with PSA in the Gray Zone of 4-10 Ng/ml

Durgesh Kumar Dwivedi1, Tarun Javali2, Rajeev Kumar2, Sanjay Thulkar3, Sanjay Sharma3, Amit K. Dinda4, Naranamangalam R. Jagannathan1

1Department of NMR & MRI Facility, All India Institute of Medical Sciences, New Delhi, Delhi, India; 2Department of Urology, All India Institute of Medical Sciences, New Delhi, Delhi, India; 3Department of Radio-diagnosis, All India Institute of Medical Sciences, New Delhi, Delhi, India; 4Department of Pathology, All India Institute of Medical Sciences, New Delhi, Delhi, India

Raised serum prostate specific antigen (PSA) may not reflect the presence of prostate cancer (PCa) and transrectal ultrasound (TRUS) has limited sensitivity in PCa detection. MRSI has the potential to detect PCa based on metabolic differences. We performed a retrospective case controlled study on 278 men prior to biopsy with PSA in the range of 4-10 ng/ml. Our study revealed that MRSI directed TRUS biopsy increases PCa detection rate (2.9 times) compared to standard TRUS guided core (6 or 12) biopsy in patients with PSA in the range of 4-10 ng/ml.

Abstract PDF Presentation Video

Keywords

abnormal accuracy accurately acquisition additional analyzing antigen approved asap atypical biopsies biopsy body cancer challenging characteristics chronic clinically committee comparing completely comprises control controlled core cores course criteria delay described despite detection determines diagnosis digital direct directed disorders done earlier early elevated eliminated ethics evaluated examination excluded facility fact findings gave gray guidance guided help highlights improve included inclusion incorporated increasing infection inflammation influence institute institutional invasive investigations known larger leading like likelihood limitations localize logistic made magma malignancy management median medical metabolites mismatch needle negative ninety overall pathology patient patients period phys poor positive potentially predictive prior procedure proliferation prospective prostate radio randomized rectal regarding retrospective role sampling scanner sciences score sensitivity sextant significantly similarly since site software sonata spans specifically specificity spectroscopic statistical statistically still suggestive systematic table targeted threshold tract treatment trials tumors twelve ultrasound unclear undergo underwent urinary urology validated versus vital volume whole written years zone